Reingle Gonzalez Jennifer M, Connell Nadine M
Jennifer M. Reingle Gonzalez is with the Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas School of Public Health, Dallas Regional Campus. Nadine M. Connell is with the University of Texas at Dallas.
Am J Public Health. 2014 Dec;104(12):2328-33. doi: 10.2105/AJPH.2014.302043. Epub 2014 Oct 16.
We assessed mental health screening and medication continuity in a nationally representative sample of US prisoners.
We obtained data from 18 185 prisoners interviewed in the 2004 Survey of Inmates in State and Federal Correctional Facilities. We conducted survey logistic regressions with Stata version 13.
About 26% of the inmates were diagnosed with a mental health condition at some point during their lifetime, and a very small proportion (18%) were taking medication for their condition(s) on admission to prison. In prison, more than 50% of those who were medicated for mental health conditions at admission did not receive pharmacotherapy in prison. Inmates with schizophrenia were most likely to receive pharmacotherapy compared with those presenting with less overt conditions (e.g., depression). This lack of treatment continuity is partially attributable to screening procedures that do not result in treatment by a medical professional in prison.
A substantial portion of the prison population is not receiving treatment for mental health conditions. This treatment discontinuity has the potential to affect both recidivism and health care costs on release from prison.
我们在美国具有全国代表性的囚犯样本中评估了心理健康筛查和药物治疗的连续性。
我们从2004年州和联邦惩教设施囚犯调查中接受访谈的18185名囚犯那里获取了数据。我们使用Stata 13版本进行了调查逻辑回归分析。
约26%的囚犯在其一生中的某个时候被诊断出患有心理健康疾病，而在入狱时因病情接受药物治疗的比例非常小（18%）。在监狱中，入狱时因心理健康状况接受药物治疗的人中，超过50%在狱中未接受药物治疗。与表现出不太明显病症（如抑郁症）的囚犯相比，患有精神分裂症的囚犯最有可能接受药物治疗。这种治疗连续性的缺乏部分归因于筛查程序未能导致监狱中的医疗专业人员进行治疗。
很大一部分监狱人口未接受心理健康疾病的治疗。这种治疗的不连续性有可能影响出狱后的累犯率和医疗保健成本。
